Independent radiological review
An independent, centralized radiological review (blinded to treatment arms) was performed to evaluate:
• Tumor response according to RECIST 1.1
• Early tumor shrinkage (ETS) (-20% diameter change) measured at 1st CT after baseline (6 weeks)
• Depth of response defined as the percentage of maximal tumor shrinkage observed at the nadir compared with baseline • ETS predicts sensitivity to treatment
• ETS predicts the potential DpR
• DpR predicts OS
Data are supported by analyses of the CRYSTAL trial demonstrating that tumor size reduction was significantly associated with OS
Summary
• An independent CT review was performed to analyse response to therapy, the primary endpoint of the FIRE-3 trial
• The independent CT review demonstrates a significantly higher ORR in the FOLFIRI plus cetuximab treated patients compared to those receiving FOLFIRI plus bevacizumab
• ETS was significantly more frequent in the cetuximab arm (p=0.0036)
• ETS was significantly associated with prolonged PFS and OS, independent of the treatment arm
• Median DpR was significantly greater in the cetuximab arm (p= 0.0004) and was highly correlated (p<0.0001) with survival
Conclusion
• The present analysis of the FIRE-3 trial indicates that response related metrics such as ETS and DpR are clearly related to OS
• Greater DpR contributes to the longer OS observed in the cetuximab arm of FIRE-3
